Heidelberg

• Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer Ended recruitment
  2023-509169-19-00 5 2017-07-11 Advanced ALK positive non-small cell lung cancer
• A study to test the safety and efficacy of the drug larotrectinib for the treatment of tumors with NTRK-fusion in children Ended recruitment
  2022-502668-20-00 9 2017-04-11 Solid tumors harboring NTRK fusion
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended recruitment
  2023-505034-10-00 4 2016-08-01 Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS
• Neoadjuvant L19IL2/L19TNF- Pivotal study Ended recruitment
  2024-515749-40-00 5 2016-02-25 Malignant melanoma of the skin in patients with locally advanced and f
• Riociguat for treatment of PAH in children from 6 to less than 18 years old Ended recruitment
  2023-503536-40-00 5 2016-02-23 Pulmonary arterial hypertension (PAH)
• A study for patients who have completed a prior global Novartis sponsored ceritinib (LDK378) study and are judged by the investigator to ben … Ended recruitment
  2024-511040-58-00 6 2016-01-12 non small cell lung cancer
• EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) wit … Ended recruitment
  2024-513509-30-00 5 2016-01-11 Progressive or recurrent germ cell tumor (measurable or non-measurable
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun … Ended recruitment
  2023-505981-26-00 5 2015-11-20 Non−Small Cell Lung Cancer
• A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations Ended recruitment
  2023-507421-41-00 1 2015-07-20 Advanced malignancies that harbor IDH1R132 mutations
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Long-Term Follow-up of Subjects With Transfusion-Dependant β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic St … Ended recruitment
  2024-513905-29-00 5 2008-10-16 Beta-thalassaemia
• NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therap … Halted
  2024-518841-12-00 9 2025-03-25 HER2 positive resectable esophagogastric adenocarcinoma
• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 5 2024-07-26 Transthyretin Amyloidosis with Cardiomyopathy
• A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small … Halted
  2023-503298-39-00 5 2024-06-13 Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator … Halted
  2024-512626-28-00 5 2024-03-28 Duchenne Muscular Dystrophy
• The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a … Halted
  2022-501322-38-00 4 2023-05-26 Non-small cell lung cancer (NSCLC)
• A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the … Halted
  2023-509451-14-00 7 2022-11-01 Metastatic uveal melanoma
• Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irin … Halted
  2024-512951-18-00 4 2021-08-06 Hepatic Oligometastatic Adenocarcinoma of the Pancreas
• A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-516889-11-00 4 2025-05-21 non-small cell lung cancer (NSCLC)
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi … Ended
  2024-512670-10-00 9 2025-02-13 Unresectable or Metastatic Melanoma
• A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or togethe … Ended
  2023-508998-85-00 1 2025-01-28 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)

Showing 553–576 of 732 trials